Dr. Roman, director of the Medical College's Kidney Center and a member of its Cardiovascular Research Center, and Taisho scientists have been working together testing the new drug for its effect on brain tissue protection shortly after a stroke. The drug helps control blood vessel dilation which can result in saving brain tissue from damage. Taisho has collaborated with Dr. Roman and funded research in his laboratory toward this end.
"The drug will now enter the path toward approval for use in humans by the FDA," explains William Hendee, Ph.D., president of the College's Research Foundation.
The Foundation patents intellectual property generated by faculty and staff at the Medical College and licenses it in line with its mission to commercialize as many inventions as possible to help patients. The Foundation believes that its "Patents to PatientsSM" brand best describes its mission. The Foundation is wholly-owned and housed within the Medical College.
Taisho is the leading over-the-counter drug company in Japan and has also been strengthening its research and development efforts including development of its research infrastructure in the area of prescription drugs. As an outcome from such efforts, Taisho has succeeded in initiating clinical trials on several original new drugs. Taisho continues efforts to strengthen its prescription drug business through expansion of its novel original research and development and active collaboration with domestic and foreign pharmaceutical companies.